Morgan Bruno
Appearances
- DateMay 9, 2023Long-term survival in patients with localized pancreatic adenocarcinoma (PDAC) or ampullary adenocarcinoma (AA) who undergo resection is rare, even in lymph node (LN)-negative disease…
Presenter
Speakers
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer CenterU.T. MD Anderson Cancer CenterUniv. Texas MD Anderson Cancer CenterBrody School of Medicine at ECU - DateMay 9, 2023Pancreatic ductal adenocarcinoma (PDAC) exists in several morphological subtypes differing in prognostic significance. However, to date, a clinico-morphological correlation of these subtypes in the context of neoadjuvant therapy (NAT) has not been performed…
Presenter
Speakers
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer CenterU.T. MD Anderson Cancer CenterUniv. Texas MD Anderson Cancer CenterBrody School of Medicine at ECU - DateMay 6, 2023LUNCH AND TRAINEE JEOPARDY! 12:00 PM - 1:00 PM LEADERSHIP FORUM, NETWORKING SESSION AND ROUNDTABLES 4:00 PM - 5:30 PM KEYNOTE ADDRESS: FUTURE SCENARIO PLANNING TO PREDICT THE FUTURE OF SURGERY 4:00 PM - 4:30 PM
Presenter
Speakers
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer CenterU.T. MD Anderson Cancer CenterUniv. Texas MD Anderson Cancer CenterBrody School of Medicine at ECU - DateMay 19, 2024BACKGROUND: Risk-stratified pancreatectomy clinical pathways (RSPCP) are associated with reduced length of stay (LOS) and major complications…
Presenter
Speakers
The University of Texas MD Anderson Cancer CenterU.T. MD Anderson Cancer CenterUniv. Texas MD Anderson Cancer CenterBrody School of Medicine at ECUThe University of Texas MD Anderson Cancer Center
